SEC22A Inhibitors
Chemical inhibitors of SEC22A can exert their inhibitory effects through various mechanisms, targeting different aspects of the cellular machinery that SEC22A relies on for its function. Brefeldin A, for instance, disrupts Golgi apparatus structure by inhibiting ADP-ribosylation factor, a critical component for vesicle formation, thereby preventing SEC22A from participating in vesicle transport. Similarly, Exo1 inhibits the Exocyst complex, which is responsible for vesicle tethering and exocytosis, processes that involve SEC22A. Nocodazole's role in inhibiting microtubule polymerization impedes the movement of vesicles along cytoskeletal tracks, hampering SEC22A's vesicular transport functions. Also targeting the Golgi apparatus, Monensin alters the ion gradients essential for vesicle formation and secretion, which leads to an inhibition of SEC22A's trafficking role.
Continuing with this theme, Dynasore interferes with vesicle scission from the Golgi by inhibiting dynamin, thus blocking the transport pathways that involve SEC22A. Cytochalasin D contributes to the inhibition by disrupting actin polymerization, a key component of cytoskeletal integrity that SEC22A utilizes for vesicular movement. Golgicide A's inhibition of the Golgi BFA resistance factor 1 disrupts ARF function, leading to compromised vesicle trafficking and thereby inhibiting SEC22A. Disruption of the actin cytoskeleton is also the mechanism by which ML141 and Latrunculin B inhibit SEC22A, as they affect Cdc42 and actin polymerization, respectively, impairing the vesicle transport machinery. Jasplakinolide, on the other hand, stabilizes actin filaments to such an extent that it prevents their necessary dynamics, inhibiting SEC22A by affecting vesicle movement and secretion processes. Finally, Salubrinal and Tunicamycin disrupt protein synthesis regulation and N-linked glycosylation, respectively, both of which are essential for the proper function of proteins that interact with SEC22A, leading to an inhibition of its role in vesicle formation and trafficking.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the Golgi apparatus structure by inhibiting the ADP-ribosylation factor (ARF), which is crucial for vesicle formation and SEC22A function in the secretory pathway. This results in inhibition of SEC22A as it can no longer participate in vesicle transport. | ||||||
Exo1 | 461681-88-9 | sc-200752 sc-200752A | 10 mg 50 mg | $84.00 $297.00 | 4 | |
Exo1, a small molecule inhibitor of Exocyst complex, can inhibit SEC22A by preventing the proper assembly and functioning of the Exocyst complex, which is essential for vesicle tethering and exocytosis where SEC22A is involved. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole disrupts microtubule polymerization, which is essential for vesicle movement along cytoskeletal tracks where SEC22A operates, leading to an inhibition of SEC22A's role in vesicular transport. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin is an ionophore that disrupts the ion gradient across the Golgi apparatus, which affects vesicle formation and secretion, thereby inhibiting SEC22A's role in the trafficking of vesicles. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore is a dynamin inhibitor that prevents the scission of vesicles from the Golgi, thus inhibiting SEC22A by blocking the vesicle transport in which it is involved. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Cytochalasin D inhibits actin polymerization, which is critical for maintaining the cytoskeleton integrity that SEC22A relies on for vesicular transport, leading to functional inhibition of SEC22A. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Golgicide A specifically inhibits the Golgi BFA resistance factor 1 (GBF1), a GEF for ARF, disrupting Golgi function and vesicle trafficking, thus inhibiting SEC22A function in vesicle budding and trafficking. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
ML141 is a potent inhibitor of Cdc42, a small GTPase involved in actin filament organization. Disrupting Cdc42 activity impairs cytoskeletal dynamics, inhibiting vesicle transport processes where SEC22A is involved. | ||||||
Latrunculin B | 76343-94-7 | sc-203318 | 1 mg | $240.00 | 29 | |
Latrunculin B binds to actin monomers and prevents their polymerization, disrupting cytoskeletal dynamics and inhibiting SEC22A function in vesicle trafficking by affecting the vesicle transport machinery. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $184.00 $305.00 | 59 | |
Jasplakinolide stabilizes actin filaments and prevents their dynamics, which are essential for vesicle movement and secretion processes involving SEC22A, leading to its inhibition. | ||||||